title: Immunogenicity of a recombinant measles HIV-1 subtype C vaccine.
abstract: The HIV epidemic is greatest in Sub-Saharan Africa and India where HIV-1 subtype C is predominant. To control the spread of HIV in these parts of the world a preventive HIV-1 subtype C vaccine is urgently required. Here we report the immunogenicity of a candidate HIV-1 subtype C vaccine delivered by a recombinant measles vector carrying an insert encoding HIV-1 subtype C Gag, RT and Nef (MV1-F4), in MHC-typed non-human primates. HIV-1 specific cytokine secreting CD4+ and CD8+ T cell responses were detected in 15 out of 16 vaccinees. These HIV-specific T cell responses persisted in lymphoid tissues. Anti-HIV-1 antibody responses were detected in 15 out of 16 vaccinees and titres were boosted by a second immunisation carried out 84 days later. These findings support further exploration of the MV1-F4 vector as a candidate HIV-1 subtype C vaccine or as part of a wider vaccine strategy.
authors.affiliation: Division of Biotherapeutics, NIBSC, Potters Bar, Hertfordshire EN6 3QG, United Kingdom. Electronic address: Richard.Stebbings@nibsc.org.
authors.forename: Richard
authors.initials: R
authors.lastname: Stebbings
authors.forename: Bo
authors.initials: B
authors.lastname: Li
authors.forename: Clarisse
authors.initials: C
authors.lastname: Lorin
authors.forename: Marguerite
authors.initials: M
authors.lastname: Koutsoukos
authors.forename: Michèle
authors.initials: M
authors.lastname: Février
authors.forename: Edward T
authors.initials: ET
authors.lastname: Mee
authors.forename: Mark
authors.initials: M
authors.lastname: Page
authors.forename: Neil
authors.initials: N
authors.lastname: Almond
authors.forename: Frédéric
authors.initials: F
authors.lastname: Tangy
authors.forename: Gérald
authors.initials: G
authors.lastname: Voss
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D016207:Cytokines / Q000378:metabolism; D004337:Drug Carriers; D005822:Genetic Vectors; D015483:HIV Antibodies / Q000097:blood; D054303:HIV Reverse Transcriptase / Q000235:genetics / Q000276:immunology; D015497:HIV-1 / Q000235:genetics / Q000276:immunology; D008252:Macaca fascicularis; D008459:Measles virus / Q000235:genetics*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D054301:gag Gene Products, Human Immunodeficiency Virus / Q000235:genetics / Q000276:immunology; D054311:nef Gene Products, Human Immunodeficiency Virus / Q000235:genetics / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D016207:Cytokines; D004337:Drug Carriers; D015483:HIV Antibodies; D014614:Vaccines, Synthetic; D054301:gag Gene Products, Human Immunodeficiency Virus; D054311:nef Gene Products, Human Immunodeficiency Virus; C514837:nef protein, Human immunodeficiency virus 1; C514824:reverse transcriptase, Human immunodeficiency virus 1; D054303:HIV Reverse Transcriptase
keywords: HIV-1 subtype C; Humoral responses; Measles; T cell responses; Vaccine; Vector